Top 10 Companies in the Ocular Drug Excipient Industry (2025): Market Leaders Driving Vision Care Innovation

In Business and finance, Global Business
September 10, 2025


The Global Ocular Drug Excipient Market was valued at USD 863 million in 2023 and is projected to reach USD 1470.45 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 6.10% during the forecast period (2023–2032). This robust growth stems from rising prevalence of ocular disorders, increasing demand for advanced drug delivery systems, and technological advancements in ophthalmic formulations.

As pharmaceutical firms develop more sophisticated treatments for conditions like glaucoma, macular degeneration, and dry eye syndrome, the importance of high-performance excipients continues to grow. These inactive ingredients play a critical role in ensuring drug stability, bioavailability, and patient tolerance. In this analysis, we examine the Top 10 Companies in the Ocular Drug Excipient Industry—pioneering formulation experts enabling next-generation ocular therapeutics.


🔟 1. BASF SE

Headquarters: Ludwigshafen, Germany
Key Offering: Kollicoat® and Soluplus® polymer systems

BASF maintains a dominant position in pharmaceutical excipients, providing specialized polymer technologies for ocular drug delivery. Their solutions enhance bioavailability and enable controlled release profiles in eye drops, gels, and implants.

Innovation Highlights:

  • Advanced pH-responsive polymers for targeted drug release
  • Customized sustained-release matrix systems
  • Patent-protected solubility enhancement platforms

Download FREE Sample Report: Ocular Drug Excipient Market – View in Detailed Research Report


9️⃣ 2. Evonik Industries AG

Headquarters: Essen, Germany
Key Offering: EUDRAGIT® polymers, RESOMER® biodegradable polymers

Evonik delivers cutting-edge polymer technologies for ocular formulations, including biodegradable implants and advanced nanoparticle delivery systems that improve corneal penetration.

Innovation Highlights:

  • Programmable release ocular implant technologies
  • Next-generation nanocarriers for gene therapy applications
  • Ion-activated in-situ gelling systems

8️⃣ 3. Roquette Frères

Headquarters: Lestrem, France
Key Offering: KLEPTOSE® cyclodextrins, PEARLITOL® mannitol

Roquette specializes in solubilizing agents and tonicity adjusters essential for ocular formulations, with their cyclodextrin technology significantly improving the solubility of hydrophobic APIs in aqueous solutions.

Innovation Highlights:

  • Advanced drug complexation technologies
  • Preservative-free formulation systems
  • Precision osmolality control solutions

7️⃣ 4. Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: Parteck® excipients, Vivacoat® film coatings

Merck’s MilliporeSigma division provides USP/EP-grade excipients for ophthalmic applications, including viscosity modifiers and mucoadhesive polymers that extend drug residence time on the ocular surface.

Innovation Highlights:

  • Hybrid nanoparticle delivery systems
  • Sterile, ready-to-use excipient platforms
  • Multi-functional excipient compounds

Download FREE Sample Report: Ocular Drug Excipient Market – View in Detailed Research Report


6️⃣ 5. Ashland Global Holdings

Headquarters: Wilmington, Delaware, USA
Key Offering: Klucel™ HPC, Plasdone™ PVP

Ashland provides critical viscosity-modifying and bioadhesive excipients for ophthalmic solutions and suspensions, formulating products that maintain optimal drug contact with ocular tissues.

Innovation Highlights:

  • Smart in-situ gelling technologies
  • Novel shear-thinning polymers
  • Drug-polymer conjugate platforms

5️⃣ 6. Dow Chemical Company

Headquarters: Midland, Michigan, USA
Key Offering: Methocel™ cellulose ethers

Dow’s cellulose-based polymers serve as premium viscosity enhancers and stabilizers for ophthalmic formulations, providing optimal rheological properties for various delivery systems.

Innovation Highlights:

  • Temperature-responsive gelation systems
  • Advanced film-forming excipients
  • Custom polymer blend solutions

4️⃣ 7. Croda International

Headquarters: Snaith, UK
Key Offering: Polyoxyl™ castor oils, Crodamol™ lipid systems

Croda provides specialized solubility enhancers and emulsion stabilizers for ocular formulations, particularly beneficial for poorly water-soluble ophthalmic compounds.

Innovation Highlights:

  • Lipid-based nano-carrier technologies
  • Self-emulsifying drug delivery platforms
  • Ophthalmic emulsion stabilization systems

3️⃣ 8. DFE Pharma

Headquarters: Goch, Germany
Key Offering: Pharmacel® MCC, Vivapur® HPMC

DFE Pharma focuses on excipients for solid ocular dosage forms, with stringent control over particle characteristics crucial for implantable and insertable drug delivery systems.

Innovation Highlights:

  • Precision-engineered controlled-release matrices
  • High-performance direct compression excipients
  • Low-dust powder handling solutions

2️⃣ 9. JRS Pharma

Headquarters: Rosenberg, Germany
Key Offering: Vivapharm® PVP, PROSOLV® silicified MCC

JRS Pharma offers customized excipient solutions for ocular tablets and dry eye therapies, emphasizing enhanced wettability and dissolution properties critical for ocular bioavailability.

Innovation Highlights:

  • Specialized spray-dried dispersions
  • Co-processed excipient combinations
  • Surface-modified cellulose derivatives

1️⃣ 10. Colorcon

Headquarters: Harleysville, Pennsylvania, USA
Key Offering: Opadry® coatings, Sustutrax™ control polymers

Colorcon provides innovative film coatings and controlled-release matrix systems for ocular dosage forms, including specialized pellet and implant technologies.

Innovation Highlights:

  • Bioerodible coating technologies
  • Precision diffusion-control matrices
  • Functional multiparticulate systems

Get Full Report Here: Ocular Drug Excipient Market – View in Detailed Research Report


🔬 Outlook: The Evolution of Ocular Excipients Towards Precision Medicine

The ocular drug excipient market is undergoing rapid transformation as formulators develop increasingly sophisticated solutions to overcome ocular barriers, with emerging technologies enabling enhanced drug penetration and extended therapeutic effects.

📈 Market Growth Drivers:

  • Development of bioresponsive “smart” excipients
  • Global shift toward preservative-free formulations
  • Rising adoption of biosimilar-compatible excipient systems
  • Integration of multiple excipient platforms in advanced delivery systems

🧪 Recent Technological Breakthroughs:

  • Nanotechnology-based penetration enhancers
  • Innovative ion-sensitive gelling polymers
  • Next-generation mucoadhesive formulations
  • Biodegradable implants with programmable release profiles

The market leaders profiled above represent the vanguard of ocular excipient innovation, enabling pharmaceutical developers to create safer, more effective vision care therapeutics through advanced formulation science.

Get Full Report Here: Ocular Drug Excipient Market – View in Detailed Research Report